• Explore /
  • Poster
  • / Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.

Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.

Abstract Video & Slides Poster

Authors

Bradley McGregor

Bradley Alexander McGregor

Dana-Farber Cancer Institute, Boston, MA

Bradley Alexander McGregor , Arjun Vasant Balar , Jonathan E. Rosenberg , Michiel Simon Van Der Heijden , Se Hoon Park , Jae-Lyun Lee , Takahiro Kojima , Michael Roger Harrison , Elisabeth I. Heath , Mark N. Stein , Yohann Loriot , Andrea Necchi , Joyce Leta Steinberg , Shang-Ying Liang , Janet Trowbridge , Daniel P. Petrylak , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT03219333

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4524)

DOI

10.1200/JCO.2021.39.15_suppl.4524

Abstract #

4524

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Terence W. Friedlander

First Author: Nataliya Mar

First Author: Peter H. O'Donnell

First Author: Jonathan E. Rosenberg